E-GEOD-36135 - Expression data from prostate cancer Docetaxel-resistant cells

Released on 2 October 2012, last updated on 19 October 2012
Homo sapiens
Samples (12)
Arrays (2)
Protocols (7)
Docetaxel is the standard first line therapy for hormone-refractory prostate cancer patients. Here we generated models of Docetaxel resistance in prostate cancer cells to study the molecular pathways that drive the acquisition of resistance to this therapy. We used microarrays to detail the global program of gene expression underlying the acquisition of Docetaxel resistance in prostate cancer cells. Parental Docetaxel-sensitive prostate cancer cell lines (DU145 and 22Rv1) and selected Docetaxel-resistant cells (DU145-DR and 22Rv1-DR) were harvested for RNA extraction and hybridization on Affymetrix microarrays. Samples were analyzed in triplicates in order to increase the resolution of expression profiles.
Experiment type
transcription profiling by array 
Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, Petrylak DP, Benson MC, Silva JM, Cordon-Cardo C. , Europe PMC 22975379
Investigation descriptionE-GEOD-36135.idf.txt
Sample and data relationshipE-GEOD-36135.sdrf.txt
Raw data (1)E-GEOD-36135.raw.1.zip
Processed data (1)E-GEOD-36135.processed.1.zip
Array designsA-AFFY-37.adf.txt, A-AFFY-44.adf.txt